MannKind Corporation

Q1 2026 revenue was $90 million, a 15% increase year over year, helped by the addition of FUROSCIX. FUROSCIX net sales were $15.5 million; Afrezza global sales were $15.3 million, up 3% year over year; collaboration and services revenue (CNS) was $23.5 million versus $29.4 million a year ago; and royalties were $32.7 million, up 9% year over year. GAAP net loss was $16.6 million, or $0.05 per share, versus GAAP net income of $13.2 million, or $0.04 per share, in Q1 2025; non-GAAP net loss was $6.9 million, or $0.02 per share, versus non-GAAP net income of $21.6 million, or $0.07 per share. The company reaffirmed full-year 2026 FUROSCIX revenue guidance of $110 million to $120 million. Management also said $5 million was received to advance ralinepag DPI, with up to $35 million in additional development milestones and a 10% royalty on net sales, and it expects about $15 million of those milestones over the next 12 months.

Michael Castagna emphasized that MannKind is evolving from a single-product company into a diversified cardiometabolic and orphan lung company, with multiple FDA-approved products and several near-term catalysts. He framed 2026 as a transformation year, pointing to the Afrezza pediatric launch, FUROSCIX ReadyFlow, and inhaled nintedanib as major value drivers. His tone was upbeat and confident, repeatedly stressing that the company is launch-ready and that underlying demand trends are improving despite a softer Q1 top line.

Chris Prentiss focused on the revenue mix, saying FUROSCIX net sales were $15.5 million and Afrezza sales were $15.3 million, while royalty revenue reached $32.7 million and CNS revenue was $23.5 million. He attributed the year-over-year decline in earnings to planned commercial investment for the two upcoming launches and to SC Pharma integration costs, including noncash amortization of acquired intangibles. He also noted that R&D is increasing as MannKind advances Phase Ib and Phase II work on MannKind 201 and that the company ended Q1 with a solid liquidity position after settling the remaining senior convertible notes, believing it has sufficient capital for planned launches and pipeline work.

Analysts focused on the pace and shape of the FUROSCIX launch, whether the $110 million to $120 million target includes both on-body and auto-injector sales, and how quickly the auto-injector could cannibalize or replace the current presentation. Management said the auto-injector is only a small part of the full-year range but should accelerate growth, with a little Q3 impact and a fuller Q4 effect if approved. Questions on ralinepag DPI centered on formulation confidence and possible once-daily dosing; Castagna said UT’s modeling guides the program, MannKind has a lead powder ready for human work, and the human data will be the real test. On Afrezza pediatrics, management said coverage should largely fit existing SKUs, success will be measured by prescribers, institutions, repeats, and hub referrals, and payer friction should improve over time as guidelines get updated.